Humacyte Inc (HUMA) concluded trading on Thursday at a closing price of $4.84, with 7.9 million shares of worth about $38.25 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -24.61% during that period and on November 14, 2024 the price saw a loss of about -9.36%. Currently the company’s common shares owned by public are about 103.67M shares, out of which, 97.86M shares are available for trading.
Stock saw a price change of -7.98% in past 5 days and over the past one month there was a price change of -16.70%. Year-to-date (YTD), HUMA shares are showing a performance of 70.42% which increased to 102.51% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.25 but also hit the highest price of $9.97 during that period. The average intraday trading volume for Humacyte Inc shares is 2.87 million. The stock is currently trading -9.64% below its 20-day simple moving average (SMA20), while that difference is down -10.85% for SMA50 and it goes to -9.91% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Humacyte Inc (NASDAQ: HUMA) currently have 103.67M outstanding shares and institutions hold larger chunk of about 26.11% of that.
The stock has a current market capitalization of $609.16M and its 3Y-monthly beta is at 1.46. It has posted earnings per share of -$1.34 in the same period. It has Quick Ratio of 1.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HUMA, volatility over the week remained 10.80% while standing at 9.21% over the month.
Stock’s fiscal year EPS is expected to drop by -22.03% while it is estimated to increase by 33.81% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 11, 2023 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by Piper Sandler stated Humacyte Inc (HUMA) stock as a Neutral in their note to investors on August 14, 2023, suggesting a price target of $3.50 for the stock. On June 22, 2023, Cantor Fitzgerald Initiated their recommendations, while on May 16, 2022, Piper Sandler Downgrade their ratings for the stock with a price target of $4. Stock get an Outperform rating from Cowen on October 29, 2021.
